B-CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION

B 细胞表位发现和抗体保护机制

• 批准号: 10706905
• 负责人: James E Crowe
• 金额: $ 200万
• 依托单位: VANDERBILT UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-16 至 2023-09-15
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10706905
• 关键词: Animal Model; Antibodies; Antibody-mediated protection; B-Lymphocyte Epitopes; Contractor; Contracts; Epitopes; GPA33 gene; Goals; Infection; Monkeypox; Monkeypox virus; Poxviridae; Prevention; Prevention approach; Prevention therapy; Proteins; Testing; Therapeutic; United States; Validation; Virion; Virus Diseases; extracellular; neutralizing antibody; nonhuman primate; programs; prophylactic; public health emergency

In 2022, monkeypox infections began to spread globally and was declared a United States public health emergency. There is an urgent need for identification of prophylactic and therapeutic approaches for prevention and treatment of monkeypox infection. The goal of this contract is to extend the validation and identification of antibody functions for monkeypox virus (MPXV) A six antibody cocktail, previously identified by the Contractor under this contract program, has shown promise for prevention and treatment of monkeypox in small animal models. However, the inclusion of six antibodies introduces significant manufacturing and regulatory challenges and there is a need to demonstrate functional utility of each antibody in prevention/therapy for MPXV infection.

2022年，猴痘感染开始在全球蔓延，美国宣布进入公共卫生紧急状态。迫切需要确定预防和治疗猴痘感染的预防和治疗方法。该合同的目标是扩大猴痘病毒（MPXV）抗体功能的验证和鉴定。承包商之前根据该合同计划鉴定出的六种抗体混合物已显示出在小动物模型中预防和治疗猴痘的前景。然而，六种抗体的纳入带来了重大的制造和监管挑战，并且需要证明每种抗体在预防/治疗 MPXV 感染中的功能效用。